Published in Dig Dis Sci on October 01, 2013
Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States. Medicine (Baltimore) (2016) 0.77
Hepatitis C Is Poorly Associated With Drug Use in Cambodian Americans in Lowell, Massachusetts. Open Forum Infect Dis (2016) 0.77
Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore) (2017) 0.75
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol (2004) 4.12
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (2002) 3.00
Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis (2010) 2.71
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol (2007) 2.35
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol (2004) 1.22
Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther (2013) 1.20
Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health (2010) 1.12
Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol (2004) 1.11
Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol (2000) 1.09
Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int (2010) 1.02
The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol (2006) 0.98
Prevalence of hepatitis C infection in New York City, 2004. J Urban Health (2009) 0.96
Hepatitis C transmission by cosmetic tattooing in women. Lancet (1996) 0.92
Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat (2011) 0.91
High proportion of hepatitis C virus in community Asian American patients with non-liver-related complaints. J Clin Gastroenterol (2013) 0.80
Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. J Viral Hepat (2011) 0.79
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Evidence of oxidative stress in human corneal diseases. J Histochem Cytochem (2002) 1.76
Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology (2002) 1.72
The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol (2005) 1.70
Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl (2003) 1.57
Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transpl (2014) 1.56
Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology (2010) 1.55
Treating hepatitis C in lower-income countries. N Engl J Med (2014) 1.52
Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology (2011) 1.49
Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol (2013) 1.48
Management of common bile duct stones in cirrhotic patients with coagulopathy: a comparison of supra-papillary puncture and standard cannulation technique. Dig Dis Sci (2011) 1.44
Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci (2009) 1.34
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology (2009) 1.32
Use of endoclips in the treatment of massive colonic diverticular bleeding. Gastrointest Endosc (2004) 1.25
Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial. Gastroenterology (2003) 1.20
Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One (2009) 1.16
Wnt transmembrane signaling and long-term spatial memory. Hippocampus (2011) 1.14
Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc (2009) 1.13
Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol (2004) 1.11
Crohn's disease associated with Sweet's syndrome and Sjögren's syndrome treated with infliximab. Clin Dev Immunol (2005) 1.03
Prevalence, risk factors, and disease knowledge of chronic hepatitis B infection in Vietnamese Americans in California. J Cancer Educ (2013) 1.03
Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int (2010) 1.02
Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action. J Gastroenterol Hepatol (2012) 1.00
Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol (2008) 0.99
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res (2010) 0.99
Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci (2011) 0.98
Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol (2012) 0.96
High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol (2012) 0.95
Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. Dig Dis Sci (2013) 0.92
Elements of the nitric oxide pathway can degrade TIMP-1 and increase gelatinase activity. Mol Vis (2004) 0.92
Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol (2009) 0.92
Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol (2008) 0.91
Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. Cancer Causes Control (2012) 0.91
Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Am J Cardiovasc Dis (2013) 0.90
Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study. Dig Dis Sci (2012) 0.89
Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J Clin Gastroenterol (2003) 0.88
Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci (2013) 0.87
Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. J Clin Gastroenterol (2013) 0.87
Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice. Eur J Gastroenterol Hepatol (2013) 0.87
Myocyte protection by 10 kD heat shock protein (Hsp10) involves the mobile loop and attenuation of the Ras GTP-ase pathway. FASEB J (2004) 0.87